Encorafenib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Encorafenib |
| DrugBank ID | DB11718 |
| Brand Names (EU) | Braftovi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.61% |
Approved Indication (EMA)
MelanomaEncorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Colorectal cancer (CRC)Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.Non-small cell lung cancer (NSCLC)Encorafenib in combination with binimetinib is indicated for the trea
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | metastatic melanoma | 97.61% | DL |
| 2 | choroideremia | 97.10% | DL |
| 3 | non-cutaneous melanoma | 96.55% | DL |
| 4 | epithelioid cell melanoma | 96.45% | DL |
| 5 | eyelid melanoma | 96.40% | DL |
| 6 | scrotum melanoma | 96.09% | DL |
| 7 | choroidal dystrophy, central areolar | 96.07% | DL |
| 8 | amelanotic skin melanoma | 95.59% | DL |
| 9 | lentigo maligna melanoma | 95.59% | DL |
| 10 | malignant melanoma of the mucosa | 95.59% | DL |
| 11 | CDK4 linked melanoma | 95.59% | DL |
| 12 | acral lentiginous melanoma (disease) | 95.59% | DL |
| 13 | superficial spreading melanoma | 95.59% | DL |
| 14 | nodular malignant melanoma | 95.59% | DL |
| 15 | balloon cell malignant melanoma | 95.59% | DL |
| 16 | intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency | 93.98% | DL |
| 17 | bilateral parasagittal parieto-occipital polymicrogyria | 86.25% | DL |
| 18 | borderline ovarian serous tumor | 85.88% | DL |
| 19 | rete ovarii cystadenoma | 85.25% | DL |
| 20 | ovarian mucinous cystadenofibroma | 85.13% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.